Children with MS - 82% lower relapse rate with Gilenya

Gilenya, or Fingolimod, is the first approved oral disease modifying drug for MS.

Children with MS - 82% lower relapse rate with Gilenya

Postby MSUK » Mon Oct 30, 2017 7:55 am

Children and adolescents with MS experience an 82% lower relapse rate with Gilenya vs. interferon beta-1a #ECTRIMS

Pharmaceutical company Novartis has released the full results of a phase III Paradigms study investigating the safety and efficiency of Gilenya (fingolimod) vs. interferon beta-1a in children and adolescents aged 10-17 with MS...Read more - http://www.ms-uk.org/children-and-adolescents-ms-experience-82-lower-relapse-rate-gilenya-vs-interferon-beta-1a-ectrims

Image
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2869
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to Gilenya

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service